These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Cutaneous CD8+ T-cell lymphoma. Regression after HIV antiviral triple therapy]. Santesteban Muruzábal R; Mitxelena Ezeiza J; Córdoba Iturriagagoitia A; Yanguas Bayona I Med Clin (Barc); 2015 Dec; 145(11):e33-4. PubMed ID: 25865613 [No Abstract] [Full Text] [Related]
7. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L; Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816 [TBL] [Abstract][Full Text] [Related]
8. 96-week CASTLE data show similar efficacy results. AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840 [No Abstract] [Full Text] [Related]
9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
10. Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Sbidian E; Battistella M; Rivet J; Flageul B; Molina JM; Joly P; Caumes E; Gorochov G; Cayuela JM; Rabian C; Dupin N; Lebbé C; Janin A; Janier M; Oksenhendler E; Bachelez H Clin Infect Dis; 2010 Sep; 51(6):741-8. PubMed ID: 20687841 [TBL] [Abstract][Full Text] [Related]
11. The art of managing human immunodeficiency virus infection: a balancing act. Reiss P Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978 [No Abstract] [Full Text] [Related]
12. [Medication change due to side effects or possible long-term complications. Side effect management with vision]. Sankawa Y MMW Fortschr Med; 2009 Apr; 151(18):35. PubMed ID: 19769072 [No Abstract] [Full Text] [Related]
13. Cutaneous borreliosis associated with T cell-predominant infiltrates: a diagnostic challenge. Kempf W; Kazakov DV; Hübscher E; Gugerli O; Gerbig AW; Schmid R; Palmedo G; Kutzner H J Am Acad Dermatol; 2015 Apr; 72(4):683-9. PubMed ID: 25617014 [TBL] [Abstract][Full Text] [Related]
14. Palpable arciform migratory erythema in an HIV patient, a CD8+ pseudolymphoma. Muche JM; Toppe E; Sterry W; Haas N J Cutan Pathol; 2004 May; 31(5):379-82. PubMed ID: 15059223 [TBL] [Abstract][Full Text] [Related]
15. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Chetchotisakd P Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438 [TBL] [Abstract][Full Text] [Related]
17. Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy. Schartz NE; De La Blanchardiére A; Alaoui S; Morel P; Sigaux F; Vignon-Pennamen MD; Flageul B; Lebbé C J Am Acad Dermatol; 2003 Jul; 49(1):139-41. PubMed ID: 12833028 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose]. García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089 [TBL] [Abstract][Full Text] [Related]
19. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037 [TBL] [Abstract][Full Text] [Related]